Literature DB >> 36267127

Novel Peptidylarginine Deiminase Type 4 (PAD4) Inhibitors.

Ram W Sabnis1.   

Abstract

Provided herein are novel compounds as peptidylarginine deiminase type 4 (PAD4) inhibitors, pharmaceutical compositions, use of such compounds in treating diseases, and processes for preparing such compounds. Published 2022 by American Chemical Society.

Entities:  

Year:  2022        PMID： 36267127      PMCID： PMC9578033          DOI： 10.1021/acsmedchemlett.2c00387

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN： 1948-5875            Impact factor:   4.632


  6 in total

Review 1.  Peptidylarginine deiminase-4: Medico-formulative strategy towards management of rheumatoid arthritis.

Authors:  Indhumathi Thirugnanasambandham; Arun Radhakrishnan; Gowthamarajan Kuppusamy; Sachin Kumar Singh; Kamal Dua
Journal:  Biochem Pharmacol       Date:  2022-04-15       Impact factor: 5.858

Review 2.  Peptidylarginine Deiminase and Alzheimer's Disease.

Authors:  Lai Wang; Hongyang Chen; Jing Tang; Zhengwei Guo; Yanming Wang
Journal:  J Alzheimers Dis       Date:  2022       Impact factor: 4.472

Review 3.  Insights into peptidylarginine deiminase expression and citrullination pathways.

Authors:  Karen Yu; Paul Proost
Journal:  Trends Cell Biol       Date:  2022-02-21       Impact factor: 21.167

Review 4.  Current knowledge into the role of the peptidylarginine deiminase (PAD) enzyme family in cardiovascular disease.

Authors:  Doa'a G F Al-U'datt; Bruce G Allen; Roddy Hiram; Nasr Alrabadi
Journal:  Eur J Pharmacol       Date:  2020-11-26       Impact factor: 4.432

Review 5.  Molecular mechanisms and therapeutic target of NETosis in diseases.

Authors:  Jiayu Huang; Weiqi Hong; Meihua Wan; Limin Zheng
Journal:  MedComm (2020)       Date:  2022-08-19

Review 6.  Crosstalk between B cells and neutrophils in rheumatoid arthritis.

Authors:  Utsa Karmakar; Sonja Vermeren
Journal:  Immunology       Date:  2021-09-08       Impact factor: 7.397
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.